Evidence map›Paper›PMID 42147064›Full record

ArticleFrontiers in cardiovascular medicine2026

Pathogenic interplay between markedly elevated plasma lipoprotein(a) levels and prothrombotic mechanisms: a case report.

Marta Biolo, Angela Napolitano, Luca Spiezia, Cristiana Bulato, Serena Toffanin, Daniela Regazzo, Camilla Portinari, Alberto Zambon, Paolo Simioni

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marta BioloDepartment of Medicine, First Chair of Internal Medicine, Padova University Hospital - School of Medicine, Padova, Italy.
Angela NapolitanoDepartment of Medicine, First Chair of Internal Medicine, Padova University Hospital - School of Medicine, Padova, Italy.
Luca SpieziaDepartment of Medicine, First Chair of Internal Medicine, Padova University Hospital - School of Medicine, Padova, Italy.
Cristiana BulatoDepartment of Medicine, First Chair of Internal Medicine, Padova University Hospital - School of Medicine, Padova, Italy.
Serena ToffaninDepartment of Medicine, First Chair of Internal Medicine, Padova University Hospital - School of Medicine, Padova, Italy.
Daniela RegazzoDepartment of Medicine, First Chair of Internal Medicine, Padova University Hospital - School of Medicine, Padova, Italy.
Camilla PortinariDepartment of Medicine, First Chair of Internal Medicine, Padova University Hospital - School of Medicine, Padova, Italy.
Alberto ZambonDepartment of Medicine, First Chair of Internal Medicine, Padova University Hospital - School of Medicine, Padova, Italy.
Paolo SimioniDepartment of Medicine, First Chair of Internal Medicine, Padova University Hospital - School of Medicine, Padova, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipoprotein(a) [Lp(a)] is a well-established genetic risk factor for atherosclerotic cardiovascular disease, though its role as a prothrombotic risk factor remains only partially understood. We report the case of a 64-year-old woman with markedly elevated Lp(a) levels (925 nmol/L, reference range < 105 nmol/L) and a history of recurrent major cardiovascular events, despite optimal lipid-lowering and antiplatelet therapies. We confirmed a hypercoagulable profile via comprehensive functional assessment of hemostasis: enhanced thrombin generation, reduced sensitivity to thrombomodulin, platelet hyperreactivity, and increased clot firmness at thromboelastometry - with residual platelet activity despite antiplatelet treatment. This case suggests a possible association between markedly elevated plasma Lp(a) levels and a hypercoagulable profile, which may enhance atherogenesis. Global coagulation and platelet function assays may help identify high-risk patients with elevated Lp(a) levels who may benefit from tailored antithrombotic strategies.

Indexed as

case reportextracellular vesicleslipoprotein(a)platelet function assaysprothrombotic riskthrombin generationthromboelastometry

Identifiers

PMID42147064
PMCPMC13175959

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.